共 33 条
[1]
Gong J(2017)Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation J Natl Compr Canc Netw 15 142-147
[2]
Wang C(2019)Immunotherapy in colorectal cancer: rationale, challenges and potential Nat Rev Gastroenterol Hepatol 16 361-375
[3]
Lee PP(2017)Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Lancet Oncol 18 1182-1191
[4]
Ganesh K(2017)Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma PLoS ONE 12 69-74
[5]
Stadler ZK(2015)Immune checkpoint modulation in colorectal cancer: what’s new and what to expect J Immunol Res 2015 396-2520
[6]
Cercek A(2015)Neoantigens in cancer immunotherapy Science 348 9037217-4
[7]
Overman MJ(2019)Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer Front Oncol 9 2509-143
[8]
McDermott R(2020)Expanding the scope of immunotherapy in colorectal cancer: current clinical approaches and future directions Biomed Res Int 2020 1-undefined
[9]
Leach JL(2015)PD-1 blockade in tumors with mismatch-repair deficiency N Engl J Med 372 135-undefined
[10]
O'Neil BH(2017)First case report of a dramatic radiographic response to a checkpoint inhibitor in a patient with proficient mismatch repair gene expressing metastatic colorectal cancer JCO Precis Oncol 1 undefined-undefined